Fluocinonide

Fluocinonide
Clinical data
Trade names	Fluonex, Lidex, others
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601054
Routes of; administration	Topical
ATC code	C05AA11 (WHO) D07AC08 (WHO), QC05AA11 (WHO), QD07AC08 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Metabolism	Liver
Identifiers
	IUPAC name 6α,9-difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone,21-acetate;
CAS Number	356-12-7 ;
PubChem CID	9642;
IUPHAR/BPS	7078;
DrugBank	DB01047 ;
ChemSpider	9265 ;
UNII	2W4A77YPAN;
KEGG	D00325 ;
ChEMBL	ChEMBL1501 ;
CompTox Dashboard (EPA)	DTXSID8045307 ;
ECHA InfoCard	100.005.998
Chemical and physical data
Formula	C26H32F2O7
Molar mass	494.532 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]45OC(O[C@@H]5C[C@@H]2[C@@]4(C[C@H](O)[C@]3(F)[C@]/1(/C=C\C(=O)\C=C\1[C@@H](F)C[C@@H]23)C)C)(C)C)C;
	InChI InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1 ; Key:WJOHZNCJWYWUJD-IUGZLZTKSA-N ;
	(verify)

Fluocinonide is a potent glucocorticoid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis.^[2] It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort.^[2]

A common potential adverse effect is skin atrophy (thinning of the skin).^[3]

In 2022, it was the 266th most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[4]^[5]

Veterinary uses

Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs.^[6] Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure.^[7]

References

^ "Fluocinonide Topical". MedlinePlus Drug Information. U.S. National Library of Medicine.
^ ^a ^b "Fluocinonide Topical: MedlinePlus Drug Information". medlineplus.gov. Retrieved 16 November 2022.
^ Jablonska S, Groniowska M, Dabroswki J (February 1979). "Comparative evaluation of skin atrophy in man induced by topical corticoids". The British Journal of Dermatology. 100 (2): 193–206. doi:10.1111/j.1365-2133.1979.tb05561.x. PMID 154921. S2CID 30656827.
^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
^ "Fluocinonide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
^ Dog Allergies. Squidoo (Report).
^ Zenoble RD, Kemppainen RJ (September 1987). "Adrenocortical suppression by topically applied corticosteroids in healthy dogs". Journal of the American Veterinary Medical Association. 191 (6): 685–688. doi:10.2460/javma.1987.191.06.685. PMID 2824410.

[1] "Fluocinonide Topical". MedlinePlus Drug Information. U.S. National Library of Medicine.

[:1-2] "Fluocinonide Topical: MedlinePlus Drug Information". medlineplus.gov. Retrieved 16 November 2022.

[:0-3] Jablonska S, Groniowska M, Dabroswki J (February 1979). "Comparative evaluation of skin atrophy in man induced by topical corticoids". The British Journal of Dermatology. 100 (2): 193–206. doi:10.1111/j.1365-2133.1979.tb05561.x. PMID 154921. S2CID 30656827.

[4] "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.

[5] "Fluocinonide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

[6] Dog Allergies. Squidoo (Report).

[7] Zenoble RD, Kemppainen RJ (September 1987). "Adrenocortical suppression by topically applied corticosteroids in healthy dogs". Journal of the American Veterinary Medical Association. 191 (6): 685–688. doi:10.2460/javma.1987.191.06.685. PMID 2824410.

[1]

[2]

[3]

[4]

[5]

[6]

[7]